Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaboration with Skyhawk Therapeutics, Inc. and Dragonfly Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CELG
Previous Symbol
CUSIP15102010
Phone908-673-9000
Debt
Debt-to-Equity Ratio4.06
Current Ratio2.13
Quick Ratio1.99
Price-To-Earnings
Trailing P/E Ratio10.20
Forward P/E Ratio9.36
P/E Growth0.43
Sales & Book Value
Annual Sales$13.00 billion
Price / Sales3.75
Cash Flow$7.6469 per share
Price / Cash Flow9.12
Book Value$8.79 per share
Price / Book7.93
Profitability
EPS (Most Recent Fiscal Year)$6.84
Net Income$2.94 billion
Net Margins19.64%
Return on Equity108.76%
Return on Assets16.75%
Miscellaneous
Employees7,467
Outstanding Shares699,250,000
Market Cap$48.59 billion
OptionableOptionable
Celgene (NASDAQ:CELG) Frequently Asked Questions
What is Celgene's stock symbol?
Celgene trades on the NASDAQ under the ticker symbol "CELG."
When did Celgene's stock split? How did Celgene's stock split work?
Celgene shares split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.
How will Celgene's stock buyback program work?
Celgene declared that its board has authorized a share buyback plan on Thursday, May 24th 2018, which authorizes the company to repurchase $3,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 5.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's leadership believes its shares are undervalued.
How were Celgene's earnings last quarter?
Celgene Co. (NASDAQ:CELG) posted its earnings results on Thursday, October, 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating the Zacks' consensus estimate of $2.02 by $0.27. The biopharmaceutical company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. View Celgene's Earnings History.
When is Celgene's next earnings date?
What guidance has Celgene issued on next quarter's earnings?
Celgene issued an update on its FY 2018 earnings guidance on Thursday, October, 25th. The company provided earnings per share (EPS) guidance of $8.75-8.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.76. The company issued revenue guidance of $15.2-15.2 billion, compared to the consensus revenue estimate of $15.17 billion.
What price target have analysts set for CELG?
28 analysts have issued twelve-month price objectives for Celgene's shares. Their predictions range from $85.00 to $166.00. On average, they expect Celgene's stock price to reach $115.5238 in the next twelve months. This suggests a possible upside of 65.6% from the stock's current price. View Analyst Price Targets for Celgene.
What is the consensus analysts' recommendation for Celgene?
28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 1 sell rating, 10 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celgene.
What are Wall Street analysts saying about Celgene stock?
Here are some recent quotes from research analysts about Celgene stock:
- 1. According to Zacks Investment Research, "Celgene’s lead drug Revlimid continue to boost performance. Other drugs like Pomalyst and Otezla are also performing well. The increase in annual guidance concurrent with the second-quarter earnings on the back of strong Revlimid sales should boost investors’ sentiment, given the recent spate of pipeline setbacks. The company is focussed on the next cycle of innovation with five late stage candidates. In a bid to revive its pipeline, Celgene acquired Juno Therapeutics and added JCAR017 to its lymphoma pipeline. Luspatercept looks promising as well with positive data from two late-stage trials. However, shares have underperformed the industry in the year so far. While Revlimid sales continue to be impressive, the company’s dependence on the same is a concern. Celgene suffered a setback when it received a Refusal To File letter from the FDA, regarding the NDA for ozanimod in relapsing multiple sclerosis (RMS)." (9/26/2018)
- 2. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call. Here are the key changes we made: ===Upward Revisions=== 1. bb2121. Added bb2121 to pipeline section of the model ($1Bn in risk- adjusted peak sales to CELG vs consensus of $900MM) 2. Luspatercept. Increased POS from 67% to 90% on the back of the recent positive Ph 3 results. (peak risk-adj sales now of $1Bn, ex-royalty to XLRN …. consensus at $850MM) ===Downward Revisions=== 3. Ozanimod MS. Trimmed peak risked adjusted sales from $1.3Bn to $1.1Bn. In total, across all 3 indications (MS, UC, CD), we carry $2.8Bn (vs consensus of $2.5Bn)." (7/31/2018)
- 3. Cowen Inc analysts commented, "We will be hosting a conference call with neurologist to discuss and TD-9855. Theravance is evaluating 1/2 trial in patients with . Results are expected to be available this month." (7/10/2018)
- 4. Canaccord Genuity analysts commented, "We expect median Progression Free Survival (PFS) > 10 months for the initial bb2121 dose escalation cohort previously reported at ASH 2017, based on 71% progression free at 9 months. Importantly, we believe PFS data could easily exceed our estimate and the 8.8 months PFS seen for pomalidomide + daratumumab + dexamethasone in Phase 1b. Duration of follow-up key for new n=21 patient cohort Investors should carefully consider the median follow-up time for the new n=21 patient bb2121 cohort with no BCMA expression cutoff, since Complete Responses improve over time. We will consider the initial bb2121 data presented at AACR in 2016, where a 78% ORR and 22% CR rate was seen. Importantly, we expect a very rapid Overall Response Rate, as seen for initial bb2121 data." (5/30/2018)
Has Celgene been receiving favorable news coverage?
News articles about CELG stock have trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Celgene earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
Are investors shorting Celgene?
Celgene saw a increase in short interest in the month of November. As of November 30th, there was short interest totalling 14,551,062 shares, an increase of 13.9% from the November 15th total of 12,773,227 shares. Based on an average daily trading volume, of 7,501,599 shares, the days-to-cover ratio is presently 1.9 days. Currently, 2.1% of the company's stock are short sold. View Celgene's Current Options Chain.
Who are some of Celgene's key competitors?
Some companies that are related to Celgene include AbbVie (ABBV), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN) and ASTELLAS PHARMA/ADR (ALPMY).
Who are Celgene's key executives?
Celgene's management team includes the folowing people:
- Mr. Mark J. Alles, Chairman & CEO (Age 59)
- Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 62)
- Dr. S. J. Rupert Vessey, Pres of Research & Early Devel. (Age 53)
- Mr. David V. Elkins, Exec. VP & CFO
- Mr. Aijaz Tobaccowalla, Sr. VP and Chief Digital & Information Officer (Age 51)
Who are Celgene's major shareholders?
Celgene's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc (7.39%), Edgewood Management LLC (2.25%), Janus Henderson Group PLC (1.50%), FMR LLC (1.47%), Franklin Resources Inc. (1.28%) and Jennison Associates LLC (1.18%). Company insiders that own Celgene stock include Ernest Mario, Gilla Kaplan, James J Loughlin, John H Weiland, Mark J Alles, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.
Which institutional investors are selling Celgene stock?
CELG stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Swedbank, Man Group plc, Panagora Asset Management Inc., Mitsubishi UFJ Trust & Banking Corp, TCW Group Inc., TIAA CREF Investment Management LLC and Vanguard Group Inc. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin and Michael D Casey. View Insider Buying and Selling for Celgene.
Which institutional investors are buying Celgene stock?
CELG stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Edgewood Management LLC, Janus Henderson Group PLC, AQR Capital Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, Glenmede Trust Co. NA and Point72 Asset Management L.P.. Company insiders that have bought Celgene stock in the last two years include John H Weiland and Mark J Alles. View Insider Buying and Selling for Celgene.
How do I buy shares of Celgene?
Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celgene's stock price today?
One share of CELG stock can currently be purchased for approximately $69.74.
How big of a company is Celgene?
Celgene has a market capitalization of $48.59 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $6.84 on an earnings per share basis. Celgene employs 7,467 workers across the globe.
What is Celgene's official website?
How can I contact Celgene?
Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]
MarketBeat Community Rating for Celgene (NASDAQ CELG)
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
